Viatris Inc. Common Stock (VTRS) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that...
Viatris Inc. Common Stock (VTRS) currently trades at a P/E ratio of 255.39 (historical range: 246.10–267.11, median: 257.82), placing it at the 40th percentile — near its historical average, P/S ratio of 1.37 (range: 0.60–1.44, 96th percentile — expensive relative to its history), EV/EBITDA of 2345.61 (range: 136.56–2792.26, 58th percentile).
Viatris Inc. Common Stock appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 255.39 | 246.10 | 257.82 | 267.11 | 40th | near its historical average |
| P/S Ratio | 1.37 | 0.60 | 0.92 | 1.44 | 96th | expensive relative to its history |
| EV/EBITDA | 2345.61 | 136.56 | 147.37 | 2792.26 | 58th | near its historical average |
| FCF Yield | 0.02 | 0.02 | 0.06 | 0.19 | 4th | expensive relative to its history |